Randomized Trial of Kamuvudine-9 (K9) in DME
Dr. Bryan Strelow
Summary
The objectives of this investigation are to assess: 1. whether oral K9 is safe in subjects with DME, and 2. whether oral K9 improves BCVA compared to oral placebo
Eligibility
- Age range
- 18+ years
- Sex
- All
- Healthy volunteers
- No
Inclusion Criteria: * Aged 18 years or older. * Diagnosis of diabetes mellitus, type 1 or 2 with non-proliferative or non-high risk proliferative diabetic retinopathy. Any one of the following will be considered sufficient evidence that diabetes is present: * Current regular use of insulin for the treatment of diabetes * Current regular use of oral hypoglycemic agents for the treatment of diabetes * DME based on investigator's clinical evaluation and evident on fundus photographs, fluorescein angiograms, or spectral domain-optical coherence tomography (SD-OCT) * HbA1c of ≤12% at screening. *…
Interventions
- DrugPlacebo Tablet: BID
Placebo tablets BID
- DrugKamuvudine K9
Kamuvudine K9
Location
- Vistar Eye CenterRoanoke, Virginia